3-(5-Bromo-2-chloropyrimidin-4-yl)-1-(phenylsulfonyl)-1H-indole

Catalog No. :
ACRNXN977
CAS No. :
1624262-44-7
Molecular Formula :
C18H11BrClN3O2S
Molecular Weight :
448.73

IUPAC Name:3-(5-bromo-2-chloropyrimidin-4-yl)-1-(phenylsulfonyl)-1H-indole

3-(5-Bromo-2-chloropyrimidin-4-yl)-1-(phenylsulfonyl)-1H-indole structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg95%$408.00Login to see priceInquiryInquiry
250mg95%$636.00Login to see priceInquiryInquiry
1g95%$1608.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name3-(5-Bromo-2-chloropyrimidin-4-yl)-1-(phenylsulfonyl)-1H-indole
IUPAC Name3-(5-bromo-2-chloropyrimidin-4-yl)-1-(phenylsulfonyl)-1H-indole
MDL No.MFCD16658984
Molecular FormulaC18H11BrClN3O2S
Molecular Weight448.73
SMILESO=S(N1C=C(C2=NC(Cl)=NC=C2Br)C3=C1C=CC=C3)(C4=CC=CC=C4)=O
InChI KeyATOBJZOVMPIWCJ-UHFFFAOYSA-N
Synonym3-(5-broMo-2-chloropyriMidin-4-yl)-1-(phenylsulfonyl)-1H-indole;1H-Indole, 3-(5-bromo-2-chloro-4-pyrimidinyl)-1-(phenylsulfonyl)-
CAS No.1624262-44-7

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H332-H335
Precautionary Statement(s)
P261-P280-P305+P351+P338

Synthetic Route by SureRoute

1. ACRNXN977 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACMHJQ375 route compound structure diagram
    ACMHJQ3751356962-87-2 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACRNXN977 route product structure diagram
    ACRNXN9771624262-44-7
Inquiry

2. ACRNXN977 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACMQXU236 route compound structure diagram
    ACMQXU236129271-98-3 In Stock
  4. Then
  5. ACRNXN977 route product structure diagram
    ACRNXN9771624262-44-7
Inquiry

Comments (0)